ArriVent BioPharma Reports Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 3, 2025
NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2024, and highlighted recent Company progress.
Read more at globenewswire.com
